CoChat

Glucagon-Like Peptide-1 (GLP-1) Receptors Expressed on Nerve Terminals in the Portal Vein Mediate the Effects of Endogenous GLP-1 on Glucose Tolerance in Rats

The DOI matches its Crossref record; 51 of the 57 references it cites were found in a registry or an index.

Abstract

Glucagon-like peptide-1 (GLP-1) is an intestinal hormone that is secreted during meal absorption and is essential for normal glucose homeostasis. However, the relatively low plasma levels and rapid metabolism of GLP-1 raise questions as to whether direct endocrine action on target organs, such as islet cells, account for all of its effects on glucose tolerance. Recently, an alternative neural pathway initiated by sensors in the hepatic portal region has been proposed to mediate GLP-1 activity. We hypothesized that visceral afferent neurons in the portal bed express the GLP-1 receptor (GLP-1r) and regulate glucose tolerance. Consistent with this hypothesis, GLP-1r mRNA was present in the nodose ganglia, and nerve terminals innervating the portal vein contained the GLP-1r. Rats given an intraportal infusion of the GLP-1r antagonist, [des-His(1),Glu(9)] exendin-4, in a low dose, had glucose intolerance, with a 53% higher glucose excursion compared with a vehicle-infused control group. Infusion of [des-His(1),Glu(9)] exendin-4 at an identical rate into the jugular vein had no effect on glucose tolerance, demonstrating that this dose of GLP-1r antagonist did not affect blood glucose due to spillover into the systemic circulation. These studies demonstrate that GLP-1r are present on nerve terminals in the hepatic portal bed and that GLP-1 antagonism localized to this region impairs glucose tolerance. These data are consistent with an important component of neural mediation of GLP-1 action.

Overview

Integrity signals

Registry

Crossref · 10.1210/en.2006-0153

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 51 references

Cited by

Metadata

Authors
Vahl, T. P., Tauchi, M., Durler, T. S., Elfers, E. E., Fernandes, T. M., Bitner, R. D., Ellis, K. S., Woods, S. C., Seeley, R. J., Herman, J. P., & D’Alessio, D. A.
Affiliations
University of Cincinnati (US)
Corresponding author
D’Alessio, David A.
Venue
Endocrinology
Published
2007-10-01
Volume
148
Issue
10
Pages
4965-4973
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
OpenAlex
W2128181185
Cited by
318
References
57
Citations by year
2026: 4 · 2025: 8 · 2024: 10 · 2023: 11 · 2022: 9 · 2021: 20 · 2020: 9 · 2019: 11 · 2018: 13 · 2017: 14 · 2016: 21 · 2015: 25 · 2014: 24 · 2013: 32 · 2012: 23
FWCI
13.40
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Cincinnati
  • National Institutes of Health (DK17844)
  • National Institute of Mental Health (MH 069680)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK 54263, DK17844, R01DK054890, DK-54890, T35DK060444)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
glucagon-like peptide-1, GLP-1 receptor, glucose tolerance, portal vein, visceral afferent neurons, nodose ganglion, exendin-4, glucose homeostasis, intraportal infusion
MeSH terms
Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Blood Glucose, Cell Line, Dose-Response Relationship, Drug, Glucose, Glucose Tolerance Test, Infusions, Intravenous, Liver, Male, Nerve Endings, Nodose Ganglion, Peptides, Portal Vein, Venoms, Rats, Sprague-Dawley, Receptors, Glucagon, Glucose Intolerance, Rats, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.